Lisa Henderson

Investors concerned with drug pricing as MFN deals reshape biopharma market access Capitol Street's Ipsita Smolinski highlights emerging challenges from voluntary agreements and regulatory shifts affecting industry strategies. Last month’s Trade and Chann... See more

AI transforms pharma finance as FDA workforce crisis disrupts drug approvals throughout 2025 Technology adoption accelerates in pharmaceutical finance operations while regulatory agency staffing challenges create unprecedented delays for companies. In Q1 ... See more

DOJ-HHS working group expands False Claims Act enforcement scope for pharma compliance officers Legal experts warn biopharma companies face broader False Claims Act litigation from DOJ-HHS working group. Legal experts from Epsilon Life Sciences posted the... See more

Pharma faces pricing upheaval as regulatory reform drives preemptive moves and multi-strategy shifts Industry expert Bill Roth warns companies must adopt diverse pricing and channel strategies as regulatory pressures reshape pharmaceutical markets Self-de... See more

Gen Z and Millennials favor Excel In the FP&A world, the ubiquitous spreadsheet is going nowhere fast. According to a survey from Datarails, there is a lot of love for Excel among the 22- to 32-year-old financial professional demographic. Although gen... See more